Grifols, S.A.
GRFSHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframePart of the healthcare sector, Grifols, S.A. (GRFS) is listed under Drug Manufacturers - General. The $5.15B market capitalization puts GRFS squarely in mid-cap range for its industry. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Market Cap
$5.15B
Beta
1.20
P/E (TTM)
9.95
P/E (Fwd)
5.24
EPS (TTM)
$0.76
EPS (Fwd)
$1.44
ROE
6.9%
ROA
4.2%
Cash
$537.0M
Total Debt
$9.36B
Free CF
$572.9M
52W Change
-19.4%
Annual Financials
Cash vs Debt
Where GRFS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, GRFS finished 0.52% below its 150-day moving average ($7.68) and 4.38% below its 200-day moving average ($7.99). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GRFS overbought or oversold?
At the October 20, 2026 close, GRFS's RSI(14) was 64.7, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, GRFS has $537.0M in cash with $9.36B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $572.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 6.9% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.2% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $6.06B (2022) to $7.52B (2025), reflecting a 24% increase over the period.
Grifols, S.A. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Grifols, S.A.'s trajectory.